Miguel Escobar

Professor (Tenure)

The University of Texas MD Anderson Cancer Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Miguel Escobar is a tenured faculty member at The University of Texas MD Anderson Cancer Center, located in the United States. His research primarily focuses on hemophilia and bleeding disorders, with recent articles exploring treatment methodologies and clinical guidelines. His work includes critical appraisals of hemorrhage management and innovative treatment options for patients with complex bleeding issues.

Articles (17)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (6)

Flora Peyvandi

Università degli Studi di Torino

ITALY

View details

AMY DUNN

Assistant Professor of Pediatrics

Emory University School of Medicine

UNITED STATES

View details

Mark Skinner

Assistant Professor (part-time)

McMaster University

CANADA

View details

Barbara Konkle

Professor of Medicine

University of Washington

UNITED STATES

View details

Frank Leebeek

Erasmus University Rotterdam

NETHERLANDS

View details

Jill Johnsen

Associate Professor

University of Washington

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Miguel Escobar

Research Interests

Explore related searches

Contact this professor

About

Articles (17)

Treatment of severe bleeds with eptacog beta in hemophilia A or B with inhibitors: a post hoc analysis of the PERSEPT 1 and 2 trials

Acute Compartment Syndrome in Congenital and Acquired Haemophilia

Retrospective chart review of GI bleeding in people with von Willebrand disease

Multicenter assessment and longitudinal study of the prevalence of antibodies and related adaptive immune responses to AAV in adult males with hemophilia

Plasma‐derived human factor X concentrate for the treatment of patients with hereditary factor X deficiency

Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease

International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia—A Critical Appraisal

Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors

Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trial

A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors

Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials

Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities to transform the care of people with hemophilia

An evaluation of von Willebrand factor (recombinant) therapy for adult patients living with severe type 3 von Willebrand disease

World federation of hemophilia international hemophilia training fellowship program: 50 years of enhancing global care

Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results

Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors

IDELVION: A Comprehensive Review of Clinical Trial and Real-World Data

Collaborators (6)

Flora Peyvandi

AMY DUNN

Mark Skinner

Barbara Konkle

Frank Leebeek

Jill Johnsen

Make your next move.